Old drugs, new tricks? A novel immunomodulatory approach to relapsed osteosarcoma therapy

Kelly Faulk, MD, a pediatric oncologist at Children's Hospital Colorado Center for Cancer and Blood Disorders, joins us on OsteoBites to review the open phase 1/1b clinical trial evaluating the combination of losartan and sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (NCT03900793), including preclinical rationale from canine clinical trials and the trial's design, eligibility, and status.Dr. Kelly Faulk is a pediatric oncologist at Children's Hospital Colorado Center for Cancer and Blood Disorders, where her clinical and research focus is the development of early-phase clinical trials to investigate promising new agents for high-risk pediatric cancers. She is on the Experimental Therapeutics Program (ETP) team and serves as the leader of the High-Risk Leukemia/Lymphoma Program. She has developed and leads several early-phase clinical trials and serves as site principal investigator for numerous others. She completed her medical training at the University of Colorado School of Medicine, did her pediatric residency and pediatric hematology/oncology/bone marrow transplant fellowship at Children's Hospital Colorado, and also completed an additional fellowship in Experimental Therapeutics at Children's Hospital Colorado. She met her wonderful husband Wade in medical school, and they have 3 great kids who keep them busy.